Know Cancer

forgot password

A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia

Phase 2
20 Years
Open (Enrolling)
Leukaemia, Lymphoblastic

Thank you

Trial Information

A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia

This study is an open-label, single arm, phase II study of chlorambucil in subjects with
previously untreated CLL.

The primary objective is to evaluate the response to chlorambucil in Japanese subjects with
previously untreated CLL.

Secondary objectives are to evaluate efficacy, safety and pharmacokinetics of chlorambucil
in Japanese subjects.

Chlorambucil is an effective and well-tolerated chemotherapeutic agent currently approved
for treatment of chronic lymphocytic leukemia (CLL) in the United States of America (US),
European Union (EU) and other countries globally but not in Japan. Other more aggressive
treatment options such as a combination of fludarabine (F) and cyclophosphamide are
available, but are associated with significantly greater toxicities. The addition of
ofatumumab to chlorambucil offers potentially a more effective therapy, with limited
additional toxicity.

Study OMB110911 has been conducted mainly in the US and EU to evaluate progression-free
survival (PFS) and overall response (OR) in subjects with previously untreated CLL with
ofatumumab in combination with chlorambucil versus (vs.) chlorambucil monotherapy.

The objective of this study is to evaluate overall response of chlorambucil in Japanese
subjects with previously untreated CLL.

Inclusion Criteria:

- Diagnosis of CLL defined by:Circulating B lymphocytes ≥5,000 /μL AND Flow cytometry
confirmation of immunophenotype with CD5, CD19, CD20, and CD23 prior to Visit 2.

- Considered inappropriate for fludarabine-based therapy.

- Active disease and indication for treatment based on the IWCLL updated NCI-WG
guidelines defined by presenting at least any one of the following conditions:
Evidence of progressive marrow failure as manifested by development or worsening of
anemia and/or thrombocytopenia.

Massive (i.e. at least 6 cm below the left costal margin) or progressive or symptomatic

Massive nodes (i.e. at least 10 cm in longest diameter) or progressive or symptomatic

Progressive lymphocytosis with an increase of more than 50% over a two month period or an
lymphocyte doubling time of less than 6 months.

A minimum of any one of the following disease-related symptoms must be present: a)
Unintentional weight loss ≥10% within the previous six months; b) Fevers >38.0°C for ≥ 2
weeks without evidence of infection; or c) Night sweats for more than 1 month without
evidence of infection

- Not been previously treated for CLL (prior autoimmune hemolytic anemia treatment with
corticosteroids permitted).

- ECOG Performance Status of 0-2.

- QTc <450 msec or QTc <480 msec for patients with bundle branch block The QTc is the
QT interval corrected for heart rate according to either Bazett's formula (QTcB) or
to Fridericia's formula (QTcF), machine or manual overread, for males and females.
The specific formula that will be used in a protocol should be determined prior to
initiation of the study, and the formula used to determine inclusion and
discontinuation should be the same throughout the study.

The QTc should be based on single or averaged QTc values of triplicate electrocardiograms
(ECGs) obtained over a brief recording period.

- Life expectancy of at least 6 months, in the opinion of the investigator.

- Age ≥ 20 years

- Signed written informed consent prior to performing any study-specific procedures
(the results of other procedures predating the informed consent can be used).

Exclusion Criteria:

- Prior immuno- or chemotherapy for CLL or small lymphocytic lymphoma (SLL) with any
agent except corticosteroids used to treat autoimmune hemolytic anemia.

- Previous autologous or allogeneic stem cell transplantation.

- Active autoimmune hemolytic anemia (AIHA) requiring corticosteroid therapy >100
mg/day equivalent to hydrocortisone, or chemotherapy.

- Known transformation of CLL (e.g. Richter).

- Known CNS involvement of CLL.

- Chronic or current active infectious disease requiring systemic antibiotics,
antifungal, or antiviral treatment such as, but not limited to, chronic renal
infection, chronic chest infection with bronchiectasis, tuberculosis and active
Hepatitis C.

- Other past or current malignancy. Subjects who have been free of malignancy for at
least 5 years, or have a history of completely resected non-melanoma skin cancer, or
successfully treated in situ carcinoma are eligible.

- Clinically significant cardiac disease including unstable angina, acute myocardial
infarction within 6 months prior to screening, congestive heart failure, and
arrhythmia requiring therapy, with the exception of extra systoles or minor
conduction abnormalities.

- History of significant cerebrovascular disease or event with significant symptoms or

- Glucocorticoid use, unless given in doses ≤ 100 mg/day hydrocortisone (or equivalent
dose of other glucocorticoid) for <7 days for exacerbations other than CLL (e.g.

- Known HIV positive.

- Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg. In
addition, if negative for HBsAg but HBcAb and/or HBsAb positive, an HBV DNA test will
be performed, and if positive the subject will be excluded.

- Screening laboratory values:

Creatinine >2.0 times upper normal limit (unless normal creatinine clearance). Total
bilirubin > 2.0 times upper normal limit (unless due to Gilbert's syndrome).

Alanine aminotransferase (ALT) > 3.0 times upper normal limit.

- Treatment with any known non-marketed drug substance or experimental therapy within 5
terminal half lives or 4 weeks prior to Visit 1, whichever is longer, treatment with
any anti-CD20 monoclonal antibody within 3 months of Visit 1, or participation in any
other interventional clinical study.

- Known or suspected inability to comply with study protocol.

- Lactating women, women with a positive pregnancy test within 7 days prior to
administration of the investigational product or women (of childbearing potential) as
well as men with partners of childbearing potential, who are not willing to use
adequate contraception from study start through one year following last treatment
dose. Adequate contraception is defined as oral hormonal birth control, intrauterine
device, and male partner sterilization (if male partner is sole partner for that
subject) and the double barrier method (condom or occlusive cap plus spermicidal

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Overall response

Outcome Description:

Number of Responders: Complete Remission (CR) and Partial Remission (PR)

Outcome Time Frame:

Up to Week 72

Safety Issue:


Principal Investigator

GSK Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:



Japan: Pharmaceuticals and Medical Devices Agency

Study ID:




Start Date:

April 2013

Completion Date:

August 2015

Related Keywords:

  • Leukaemia, Lymphoblastic
  • Leukemia
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Leukemia, Lymphoid
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma